JP2018504449A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018504449A5 JP2018504449A5 JP2017541860A JP2017541860A JP2018504449A5 JP 2018504449 A5 JP2018504449 A5 JP 2018504449A5 JP 2017541860 A JP2017541860 A JP 2017541860A JP 2017541860 A JP2017541860 A JP 2017541860A JP 2018504449 A5 JP2018504449 A5 JP 2018504449A5
- Authority
- JP
- Japan
- Prior art keywords
- amino
- fluoro
- bipyridin
- pyrimidin
- bipyridine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- 150000001875 compounds Chemical class 0.000 claims 7
- -1 hydroxy, amino Chemical group 0.000 claims 6
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 3
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 239000000126 substance Substances 0.000 claims 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 2
- 208000014644 Brain disease Diseases 0.000 claims 2
- MRPWZEBLZITJRD-UHFFFAOYSA-N CN(CC1)CCC1C1=CC(C2=CC=CC(C(C=CN=C3N)=C3F)=N2)=NC(N)=N1 Chemical compound CN(CC1)CCC1C1=CC(C2=CC=CC(C(C=CN=C3N)=C3F)=N2)=NC(N)=N1 MRPWZEBLZITJRD-UHFFFAOYSA-N 0.000 claims 2
- 102000003903 Cyclin-dependent kinases Human genes 0.000 claims 2
- 108090000266 Cyclin-dependent kinases Proteins 0.000 claims 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 2
- QXRDCVLYOCTQRA-UHFFFAOYSA-N NC1=NC=CC(=C1F)C1=NC(=CC=C1)C1=NC(=NC(=C1C)C1CCN(CC1)C(C)C)N Chemical compound NC1=NC=CC(=C1F)C1=NC(=CC=C1)C1=NC(=NC(=C1C)C1CCN(CC1)C(C)C)N QXRDCVLYOCTQRA-UHFFFAOYSA-N 0.000 claims 2
- HVKXBOWCLHMPRY-UHFFFAOYSA-N NC1=NC=CC(=C1F)C1=NC(=CC=C1)C1=NC(=NC(=C1C)C1CCN(CC1)C)N Chemical compound NC1=NC=CC(=C1F)C1=NC(=CC=C1)C1=NC(=NC(=C1C)C1CCN(CC1)C)N HVKXBOWCLHMPRY-UHFFFAOYSA-N 0.000 claims 2
- XOVJLFUZECUJFT-UHFFFAOYSA-N NC1=NC=CC(=C1F)C1=NC(=CC=C1)C1=NC(=NC(=C1C)C1CCN(CC1)CC)N Chemical compound NC1=NC=CC(=C1F)C1=NC(=CC=C1)C1=NC(=NC(=C1C)C1CCN(CC1)CC)N XOVJLFUZECUJFT-UHFFFAOYSA-N 0.000 claims 2
- IXTJGGRZWJFXNL-UHFFFAOYSA-N NC1=NC=CC(=C1F)C1=NC(=CC=C1)C1=NC(=NC(=C1C)C1CCN(CC1)CCC)N Chemical compound NC1=NC=CC(=C1F)C1=NC(=CC=C1)C1=NC(=NC(=C1C)C1CCN(CC1)CCC)N IXTJGGRZWJFXNL-UHFFFAOYSA-N 0.000 claims 2
- XREIJTDAGVIUTJ-UHFFFAOYSA-N NC1=NC=CC(=C1F)C1=NC(=CC=C1)C1=NC(=NC(=C1C)C1CN(CCC1)C(C)C)N Chemical compound NC1=NC=CC(=C1F)C1=NC(=CC=C1)C1=NC(=NC(=C1C)C1CN(CCC1)C(C)C)N XREIJTDAGVIUTJ-UHFFFAOYSA-N 0.000 claims 2
- LQAIGLHYAGUIEN-UHFFFAOYSA-N NC1=NC=CC(=C1F)C1=NC(=CC=C1)C1=NC(=NC(=C1C)C1CN(CCC1)CCC)N Chemical compound NC1=NC=CC(=C1F)C1=NC(=CC=C1)C1=NC(=NC(=C1C)C1CN(CCC1)CCC)N LQAIGLHYAGUIEN-UHFFFAOYSA-N 0.000 claims 2
- AMDCZTGQWVIMSH-UHFFFAOYSA-N NC1=NC=CC(=C1F)C1=NC(=CC=C1)N1C(N=C(C(=C1)C)C1CN(CCC1)C)N Chemical compound NC1=NC=CC(=C1F)C1=NC(=CC=C1)N1C(N=C(C(=C1)C)C1CN(CCC1)C)N AMDCZTGQWVIMSH-UHFFFAOYSA-N 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims 2
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 230000003412 degenerative effect Effects 0.000 claims 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 claims 2
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 claims 2
- 229910052736 halogen Chemical group 0.000 claims 2
- 150000002367 halogens Chemical group 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 229960004964 temozolomide Drugs 0.000 claims 2
- WYDUSKDSKCASEF-LJQANCHMSA-N (1s)-1-cyclohexyl-1-phenyl-3-pyrrolidin-1-ylpropan-1-ol Chemical compound C([C@](O)(C1CCCCC1)C=1C=CC=CC=1)CN1CCCC1 WYDUSKDSKCASEF-LJQANCHMSA-N 0.000 claims 1
- MKJIEFSOBYUXJB-HOCLYGCPSA-N (3S,11bS)-9,10-dimethoxy-3-isobutyl-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one Chemical compound C1CN2C[C@H](CC(C)C)C(=O)C[C@H]2C2=C1C=C(OC)C(OC)=C2 MKJIEFSOBYUXJB-HOCLYGCPSA-N 0.000 claims 1
- VFVAQKKPFOPZEA-UHFFFAOYSA-N 2,6-bis(2-aminopyrimidin-4-yl)pyridin-3-ol Chemical compound NC1=NC=CC(=N1)C1=NC(=CC=C1O)C1=NC(=NC=C1)N VFVAQKKPFOPZEA-UHFFFAOYSA-N 0.000 claims 1
- VBKVZSGLBSHDDY-UHFFFAOYSA-N 2-(2-amino-5,6-dimethylpyrimidin-4-yl)-6-(2-amino-3-fluoropyridin-4-yl)pyridin-3-ol Chemical compound NC1=NC=CC(=C1F)C1=NC(=C(C=C1)O)C1=NC(=NC(=C1C)C)N VBKVZSGLBSHDDY-UHFFFAOYSA-N 0.000 claims 1
- CDXHEZRZLZUFTF-UHFFFAOYSA-N 2-(2-amino-5-ethylpyrimidin-4-yl)-6-(2-amino-3-fluoropyridin-4-yl)pyridin-3-ol Chemical compound NC1=NC=CC(=C1F)C1=NC(=C(C=C1)O)C1=NC(=NC=C1CC)N CDXHEZRZLZUFTF-UHFFFAOYSA-N 0.000 claims 1
- ULKJKOOARLOSTC-UHFFFAOYSA-N 2-(2-amino-6-chloropyrimidin-4-yl)-6-pyridin-4-ylpyridin-3-ol Chemical compound NC1=NC(=CC(=N1)C1=C(C=CC(=N1)C1=CC=NC=C1)O)Cl ULKJKOOARLOSTC-UHFFFAOYSA-N 0.000 claims 1
- PXPDMILZOQXUSI-UHFFFAOYSA-N 2-(2-amino-6-methylpyrimidin-4-yl)-6-(2,3-difluoro-4-hydroxyphenyl)pyridin-3-ol Chemical compound NC1=NC(=CC(=N1)C1=NC(=CC=C1O)C1=C(C(=C(C=C1)O)F)F)C PXPDMILZOQXUSI-UHFFFAOYSA-N 0.000 claims 1
- CJUCXVYWERHIBR-UHFFFAOYSA-N 2-(2-amino-6-methylpyrimidin-4-yl)-6-(2-fluoro-4-hydroxyphenyl)pyridin-3-ol Chemical compound NC1=NC(=CC(=N1)C1=NC(=CC=C1O)C1=C(C=C(C=C1)O)F)C CJUCXVYWERHIBR-UHFFFAOYSA-N 0.000 claims 1
- IWPJRURSBORDGS-UHFFFAOYSA-N 2-(2-amino-6-methylpyrimidin-4-yl)-6-(3-aminophenyl)pyridin-3-ol Chemical compound NC1=NC(=CC(=N1)C1=NC(=CC=C1O)C1=CC(=CC=C1)N)C IWPJRURSBORDGS-UHFFFAOYSA-N 0.000 claims 1
- MWTAGVAWBLPBMP-UHFFFAOYSA-N 2-(2-amino-6-methylpyrimidin-4-yl)-6-(3-fluoropyridin-4-yl)pyridin-3-ol Chemical compound NC1=NC(=CC(=N1)C1=C(C=CC(=N1)C1=C(C=NC=C1)F)O)C MWTAGVAWBLPBMP-UHFFFAOYSA-N 0.000 claims 1
- BDSAWBGLYKUYDH-UHFFFAOYSA-N 2-(2-amino-6-methylpyrimidin-4-yl)-6-(4-hydroxyphenyl)pyridin-3-ol Chemical compound NC1=NC(=CC(=N1)C1=NC(=CC=C1O)C1=CC=C(C=C1)O)C BDSAWBGLYKUYDH-UHFFFAOYSA-N 0.000 claims 1
- QYVXMISLDOLJLZ-UHFFFAOYSA-N 2-(2-amino-6-methylpyrimidin-4-yl)-6-pyridin-4-ylpyridin-3-ol Chemical compound NC1=NC(=CC(=N1)C1=C(C=CC(=N1)C1=CC=NC=C1)O)C QYVXMISLDOLJLZ-UHFFFAOYSA-N 0.000 claims 1
- IUURGEAKIXULKZ-UHFFFAOYSA-N 2-(2-aminopyrimidin-4-yl)-6-(2,3-difluoro-4-hydroxyphenyl)pyridin-3-ol Chemical compound NC1=NC=CC(=N1)C1=NC(=CC=C1O)C1=C(C(=C(C=C1)O)F)F IUURGEAKIXULKZ-UHFFFAOYSA-N 0.000 claims 1
- XVKXFIJMBDLXDL-UHFFFAOYSA-N 2-(2-aminopyrimidin-4-yl)-6-(2-fluoro-4-hydroxyphenyl)pyridin-3-ol Chemical compound NC1=NC=CC(=N1)C1=NC(=CC=C1O)C1=C(C=C(C=C1)O)F XVKXFIJMBDLXDL-UHFFFAOYSA-N 0.000 claims 1
- ZGWYJFSRHJXDKB-UHFFFAOYSA-N 2-(2-aminopyrimidin-4-yl)-6-(3-fluoro-4-hydroxyphenyl)pyridin-3-ol Chemical compound NC1=NC=CC(=N1)C1=NC(=CC=C1O)C1=CC(=C(C=C1)O)F ZGWYJFSRHJXDKB-UHFFFAOYSA-N 0.000 claims 1
- AHUDUDDFNZTMJJ-UHFFFAOYSA-N 2-(2-aminopyrimidin-4-yl)-6-(3-fluoropyridin-4-yl)pyridin-3-ol Chemical compound NC1=NC=CC(=N1)C1=C(C=CC(=N1)C1=C(C=NC=C1)F)O AHUDUDDFNZTMJJ-UHFFFAOYSA-N 0.000 claims 1
- IXMABNBCBJZVRT-UHFFFAOYSA-N 2-(2-aminopyrimidin-4-yl)-6-(3-hydroxyphenyl)pyridin-3-ol Chemical compound NC1=NC=CC(=N1)C1=NC(=CC=C1O)C1=CC(=CC=C1)O IXMABNBCBJZVRT-UHFFFAOYSA-N 0.000 claims 1
- CTTUZLCFYRLJOD-UHFFFAOYSA-N 2-(2-aminopyrimidin-4-yl)-6-(4-hydroxyphenyl)pyridin-3-ol Chemical compound NC1=NC=CC(=N1)C1=NC(=CC=C1O)C1=CC=C(C=C1)O CTTUZLCFYRLJOD-UHFFFAOYSA-N 0.000 claims 1
- CNJSKIQGLFEHSM-UHFFFAOYSA-N 2-(2-aminopyrimidin-4-yl)-6-pyridin-3-ylpyridin-3-ol Chemical compound NC1=NC=CC(=N1)C1=C(C=CC(=N1)C=1C=NC=CC=1)O CNJSKIQGLFEHSM-UHFFFAOYSA-N 0.000 claims 1
- BGGFKMXFAFRLKE-UHFFFAOYSA-N 2-(2-aminopyrimidin-4-yl)-6-pyridin-4-ylpyridin-3-ol Chemical compound NC1=NC=CC(=N1)C1=C(C=CC(=N1)C1=CC=NC=C1)O BGGFKMXFAFRLKE-UHFFFAOYSA-N 0.000 claims 1
- KOCDBXMUNMZOFD-UHFFFAOYSA-N 2-[2-amino-6-(1-ethylpiperidin-3-yl)pyrimidin-4-yl]-6-(2-amino-3-fluoropyridin-4-yl)pyridin-3-ol Chemical compound NC1=NC=CC(=C1F)C1=NC(=C(C=C1)O)C1=NC(=NC(=C1)C1CN(CCC1)CC)N KOCDBXMUNMZOFD-UHFFFAOYSA-N 0.000 claims 1
- JVFWWWWRIZOYBC-UHFFFAOYSA-N 2-[2-amino-6-(1-ethylpiperidin-4-yl)pyrimidin-4-yl]-6-(2-amino-3-fluoropyridin-4-yl)pyridin-3-ol Chemical compound NC1=NC=CC(=C1F)C1=NC(=C(C=C1)O)C1=NC(=NC(=C1)C1CCN(CC1)CC)N JVFWWWWRIZOYBC-UHFFFAOYSA-N 0.000 claims 1
- KHITZQQFUDDYOY-UHFFFAOYSA-N 2-[2-amino-6-(dimethylamino)pyrimidin-4-yl]-6-(2-amino-3-fluoropyridin-4-yl)pyridin-3-ol Chemical compound NC1=NC=CC(=C1F)C1=NC(=C(C=C1)O)C1=NC(=NC(=C1)N(C)C)N KHITZQQFUDDYOY-UHFFFAOYSA-N 0.000 claims 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims 1
- FKVHEFZQWCSWPF-UHFFFAOYSA-N 6-(2-amino-3-fluoropyridin-4-yl)-2-(2-amino-5-methylpyrimidin-4-yl)pyridin-3-ol Chemical compound NC1=NC=CC(=C1F)C1=NC(=C(C=C1)O)C1=NC(=NC=C1C)N FKVHEFZQWCSWPF-UHFFFAOYSA-N 0.000 claims 1
- ZPIBLZXCXVBUFZ-UHFFFAOYSA-N 6-(2-amino-3-fluoropyridin-4-yl)-2-(2-amino-5-propylpyrimidin-4-yl)pyridin-3-ol Chemical compound NC1=NC=CC(=C1F)C1=NC(=C(C=C1)O)C1=NC(=NC=C1CCC)N ZPIBLZXCXVBUFZ-UHFFFAOYSA-N 0.000 claims 1
- UQHDKUFLWKTTDL-UHFFFAOYSA-N 6-(2-amino-3-fluoropyridin-4-yl)-2-(2-amino-6-methylpyrimidin-4-yl)pyridin-3-ol Chemical compound NC1=NC=CC(=C1F)C1=NC(=C(C=C1)O)C1=NC(=NC(=C1)C)N UQHDKUFLWKTTDL-UHFFFAOYSA-N 0.000 claims 1
- SFMPGAKXIHSIGO-UHFFFAOYSA-N 6-(2-amino-3-fluoropyridin-4-yl)-2-(2-amino-6-morpholin-4-ylpyrimidin-4-yl)pyridin-3-ol Chemical compound NC1=NC=CC(=C1F)C1=NC(=C(C=C1)O)C1=NC(=NC(=C1)N1CCOCC1)N SFMPGAKXIHSIGO-UHFFFAOYSA-N 0.000 claims 1
- ICLXIERULPGRLV-UHFFFAOYSA-N 6-(2-amino-3-fluoropyridin-4-yl)-2-(2-amino-6-piperidin-4-ylpyrimidin-4-yl)pyridin-3-ol Chemical compound NC1=NC=CC(=C1F)C1=NC(=C(C=C1)O)C1=NC(=NC(=C1)C1CCNCC1)N ICLXIERULPGRLV-UHFFFAOYSA-N 0.000 claims 1
- DJRWECZCVWWHFC-UHFFFAOYSA-N 6-(2-amino-3-fluoropyridin-4-yl)-2-(2-amino-6-propan-2-ylpyrimidin-4-yl)pyridin-3-ol Chemical compound NC1=NC=CC(=C1F)C1=NC(=C(C=C1)O)C1=NC(=NC(=C1)C(C)C)N DJRWECZCVWWHFC-UHFFFAOYSA-N 0.000 claims 1
- LWMNKYLPBXRTDQ-UHFFFAOYSA-N 6-(2-amino-3-fluoropyridin-4-yl)-2-[2-amino-6-(1-methylpiperidin-3-yl)pyrimidin-4-yl]pyridin-3-ol Chemical compound NC1=NC=CC(=C1F)C1=NC(=C(C=C1)O)C1=NC(=NC(=C1)C1CN(CCC1)C)N LWMNKYLPBXRTDQ-UHFFFAOYSA-N 0.000 claims 1
- AQTUVYRUTYHIJX-UHFFFAOYSA-N 6-(2-amino-3-fluoropyridin-4-yl)-2-[2-amino-6-(1-methylpiperidin-4-yl)pyrimidin-4-yl]pyridin-3-ol Chemical compound NC1=NC=CC(=C1F)C1=NC(=C(C=C1)O)C1=NC(=NC(=C1)C1CCN(CC1)C)N AQTUVYRUTYHIJX-UHFFFAOYSA-N 0.000 claims 1
- YVSZJKLHXVFEQB-UHFFFAOYSA-N 6-(2-amino-3-fluoropyridin-4-yl)-2-[2-amino-6-(1-propan-2-ylpiperidin-3-yl)pyrimidin-4-yl]pyridin-3-ol Chemical compound NC1=NC=CC(=C1F)C1=NC(=C(C=C1)O)C1=NC(=NC(=C1)C1CN(CCC1)C(C)C)N YVSZJKLHXVFEQB-UHFFFAOYSA-N 0.000 claims 1
- DFUJTWCORWDBOJ-UHFFFAOYSA-N 6-(2-amino-3-fluoropyridin-4-yl)-2-[2-amino-6-(1-propan-2-ylpiperidin-4-yl)pyrimidin-4-yl]pyridin-3-ol Chemical compound NC1=NC=CC(=C1F)C1=NC(=C(C=C1)O)C1=NC(=NC(=C1)C1CCN(CC1)C(C)C)N DFUJTWCORWDBOJ-UHFFFAOYSA-N 0.000 claims 1
- JYTCKBDBQPIRRN-UHFFFAOYSA-N 6-(2-amino-3-fluoropyridin-4-yl)-2-[2-amino-6-(1-propylpiperidin-3-yl)pyrimidin-4-yl]pyridin-3-ol Chemical compound NC1=NC=CC(=C1F)C1=NC(=C(C=C1)O)C1=NC(=NC(=C1)C1CN(CCC1)CCC)N JYTCKBDBQPIRRN-UHFFFAOYSA-N 0.000 claims 1
- XUJAXYRASNBVNZ-UHFFFAOYSA-N 6-(2-amino-3-fluoropyridin-4-yl)-2-[2-amino-6-(1-propylpiperidin-4-yl)pyrimidin-4-yl]pyridin-3-ol Chemical compound NC1=NC=CC(=C1F)C1=NC(=C(C=C1)O)C1=NC(=NC(=C1)C1CCN(CC1)CCC)N XUJAXYRASNBVNZ-UHFFFAOYSA-N 0.000 claims 1
- MNJURBQBWJJSAF-UHFFFAOYSA-N 6-(2-amino-3-fluoropyridin-4-yl)-2-[2-amino-6-(4-methylpiperazin-1-yl)pyrimidin-4-yl]pyridin-3-ol Chemical compound NC1=NC=CC(=C1F)C1=NC(=C(C=C1)O)C1=NC(=NC(=C1)N1CCN(CC1)C)N MNJURBQBWJJSAF-UHFFFAOYSA-N 0.000 claims 1
- YWMJCIOQXWGOKM-UHFFFAOYSA-N 6-(2-amino-3-fluoropyridin-4-yl)-2-[2-amino-6-(oxan-4-yl)pyrimidin-4-yl]pyridin-3-ol Chemical compound NC1=NC=CC(=C1F)C1=NC(=C(C=C1)O)C1=NC(=NC(=C1)C1CCOCC1)N YWMJCIOQXWGOKM-UHFFFAOYSA-N 0.000 claims 1
- SGGNFNDFFIZBJK-UHFFFAOYSA-N 6-(2-amino-3-hydroxypyridin-4-yl)-2-(2-aminopyrimidin-4-yl)pyridin-3-ol Chemical compound NC1=NC=CC(=C1O)C1=NC(=C(C=C1)O)C1=NC(=NC=C1)N SGGNFNDFFIZBJK-UHFFFAOYSA-N 0.000 claims 1
- IJDIWAFBPDXFMW-UHFFFAOYSA-N 6-(2-aminopyridin-4-yl)-2-(2-aminopyrimidin-4-yl)pyridin-3-ol Chemical compound NC1=NC=CC(=C1)C1=NC(=C(C=C1)O)C1=NC(=NC=C1)N IJDIWAFBPDXFMW-UHFFFAOYSA-N 0.000 claims 1
- JQZYCLXXQNKVFS-UHFFFAOYSA-N 6-(3-amino-2-fluorophenyl)-2-(2-aminopyrimidin-4-yl)pyridin-3-ol Chemical compound NC=1C(=C(C=CC=1)C1=CC=C(C(=N1)C1=NC(=NC=C1)N)O)F JQZYCLXXQNKVFS-UHFFFAOYSA-N 0.000 claims 1
- CNHZNVAIYWPGGP-UHFFFAOYSA-N 6-(3-aminophenyl)-2-(2-aminopyrimidin-4-yl)pyridin-3-ol Chemical compound NC=1C=C(C=CC=1)C1=CC=C(C(=N1)C1=NC(=NC=C1)N)O CNHZNVAIYWPGGP-UHFFFAOYSA-N 0.000 claims 1
- LBGNAGATQGHENE-UHFFFAOYSA-N 6-(3-fluoropyridin-4-yl)pyridin-3-ol Chemical compound FC=1C=NC=CC=1C1=NC=C(C=C1)O LBGNAGATQGHENE-UHFFFAOYSA-N 0.000 claims 1
- ICMIEIUORHDHSN-UHFFFAOYSA-N 6-(4-amino-2-fluorophenyl)-2-(2-aminopyrimidin-4-yl)pyridin-3-ol Chemical compound NC1=CC(=C(C=C1)C1=CC=C(C(=N1)C1=NC(=NC=C1)N)O)F ICMIEIUORHDHSN-UHFFFAOYSA-N 0.000 claims 1
- WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 108010006654 Bleomycin Proteins 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- OSOXRYLPBUUASC-UHFFFAOYSA-N C(C)(=O)O.C(C)(=O)O.NC1=NC=CC(=C1F)C1=NC(=C(C=C1)O)C1=NC(=NC(=C1)C(C)C)N Chemical compound C(C)(=O)O.C(C)(=O)O.NC1=NC=CC(=C1F)C1=NC(=C(C=C1)O)C1=NC(=NC(=C1)C(C)C)N OSOXRYLPBUUASC-UHFFFAOYSA-N 0.000 claims 1
- JSGACLAEWRXPFQ-UHFFFAOYSA-N C(CC(=O)O)(=O)O.C(CC(=O)O)(=O)O.NC1=NC=CC(=C1F)C1=NC(=C(C=C1)O)C1=NC(=NC=C1)N Chemical compound C(CC(=O)O)(=O)O.C(CC(=O)O)(=O)O.NC1=NC=CC(=C1F)C1=NC(=C(C=C1)O)C1=NC(=NC=C1)N JSGACLAEWRXPFQ-UHFFFAOYSA-N 0.000 claims 1
- ITOJUADUQZMPQD-UHFFFAOYSA-N CCC1=C(N=C(N=C1C2CCN(CC2)C(C)C)N)C3=C(C=CC(=N3)C4=C(C(=NC=C4)N)F)O.Cl.Cl.Cl.Cl Chemical compound CCC1=C(N=C(N=C1C2CCN(CC2)C(C)C)N)C3=C(C=CC(=N3)C4=C(C(=NC=C4)N)F)O.Cl.Cl.Cl.Cl ITOJUADUQZMPQD-UHFFFAOYSA-N 0.000 claims 1
- ZCKGBISRBLIOEI-UHFFFAOYSA-N CNC1=NC(=CC(=N1)C2CCN(CC2)C)C3=CC=CC(=N3)C4=C(C(=NC=C4)N)F Chemical compound CNC1=NC(=CC(=N1)C2CCN(CC2)C)C3=CC=CC(=N3)C4=C(C(=NC=C4)N)F ZCKGBISRBLIOEI-UHFFFAOYSA-N 0.000 claims 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 claims 1
- QPDXASUPSXMSNL-UHFFFAOYSA-N Cl.Cl.Cl.Cl.Cl.NC1=NC=CC(=C1F)C1=NC(=C(C=C1)O)C1=NC(=NC(=C1)N1CCN(CC1)C)N Chemical compound Cl.Cl.Cl.Cl.Cl.NC1=NC=CC(=C1F)C1=NC(=C(C=C1)O)C1=NC(=NC(=C1)N1CCN(CC1)C)N QPDXASUPSXMSNL-UHFFFAOYSA-N 0.000 claims 1
- GOIUPTLFGOYJCA-UHFFFAOYSA-N Cl.Cl.Cl.Cl.NC1=NC=CC(=C1F)C1=NC(=C(C=C1)O)C1=NC(=NC(=C1)C1CCN(CC1)C(C)C)N Chemical compound Cl.Cl.Cl.Cl.NC1=NC=CC(=C1F)C1=NC(=C(C=C1)O)C1=NC(=NC(=C1)C1CCN(CC1)C(C)C)N GOIUPTLFGOYJCA-UHFFFAOYSA-N 0.000 claims 1
- GWOMEQPBGHZJGO-UHFFFAOYSA-N Cl.Cl.Cl.Cl.NC1=NC=CC(=C1F)C1=NC(=C(C=C1)O)C1=NC(=NC(=C1)C1CCN(CC1)C)N Chemical compound Cl.Cl.Cl.Cl.NC1=NC=CC(=C1F)C1=NC(=C(C=C1)O)C1=NC(=NC(=C1)C1CCN(CC1)C)N GWOMEQPBGHZJGO-UHFFFAOYSA-N 0.000 claims 1
- DDVZOQMYHBIASZ-UHFFFAOYSA-N Cl.Cl.Cl.Cl.NC1=NC=CC(=C1F)C1=NC(=C(C=C1)O)C1=NC(=NC(=C1)C1CCN(CC1)CC)N Chemical compound Cl.Cl.Cl.Cl.NC1=NC=CC(=C1F)C1=NC(=C(C=C1)O)C1=NC(=NC(=C1)C1CCN(CC1)CC)N DDVZOQMYHBIASZ-UHFFFAOYSA-N 0.000 claims 1
- FYYYZMNGKORBLH-UHFFFAOYSA-N Cl.Cl.Cl.Cl.NC1=NC=CC(=C1F)C1=NC(=C(C=C1)O)C1=NC(=NC(=C1)C1CCN(CC1)CCC)N Chemical compound Cl.Cl.Cl.Cl.NC1=NC=CC(=C1F)C1=NC(=C(C=C1)O)C1=NC(=NC(=C1)C1CCN(CC1)CCC)N FYYYZMNGKORBLH-UHFFFAOYSA-N 0.000 claims 1
- KCCIQQBMNOGMKB-UHFFFAOYSA-N Cl.Cl.Cl.Cl.NC1=NC=CC(=C1F)C1=NC(=C(C=C1)O)C1=NC(=NC(=C1)C1CCNCC1)N Chemical compound Cl.Cl.Cl.Cl.NC1=NC=CC(=C1F)C1=NC(=C(C=C1)O)C1=NC(=NC(=C1)C1CCNCC1)N KCCIQQBMNOGMKB-UHFFFAOYSA-N 0.000 claims 1
- KDBUHCFIJXGUJJ-UHFFFAOYSA-N Cl.Cl.Cl.Cl.NC1=NC=CC(=C1F)C1=NC(=C(C=C1)O)C1=NC(=NC(=C1)C1CN(CCC1)C(C)C)N Chemical compound Cl.Cl.Cl.Cl.NC1=NC=CC(=C1F)C1=NC(=C(C=C1)O)C1=NC(=NC(=C1)C1CN(CCC1)C(C)C)N KDBUHCFIJXGUJJ-UHFFFAOYSA-N 0.000 claims 1
- XNZICOBNYGNIPR-UHFFFAOYSA-N Cl.Cl.Cl.Cl.NC1=NC=CC(=C1F)C1=NC(=C(C=C1)O)C1=NC(=NC(=C1)C1CN(CCC1)C)N Chemical compound Cl.Cl.Cl.Cl.NC1=NC=CC(=C1F)C1=NC(=C(C=C1)O)C1=NC(=NC(=C1)C1CN(CCC1)C)N XNZICOBNYGNIPR-UHFFFAOYSA-N 0.000 claims 1
- CQAZBIQKXHIXMW-UHFFFAOYSA-N Cl.Cl.Cl.Cl.NC1=NC=CC(=C1F)C1=NC(=C(C=C1)O)C1=NC(=NC(=C1)C1CN(CCC1)CC)N Chemical compound Cl.Cl.Cl.Cl.NC1=NC=CC(=C1F)C1=NC(=C(C=C1)O)C1=NC(=NC(=C1)C1CN(CCC1)CC)N CQAZBIQKXHIXMW-UHFFFAOYSA-N 0.000 claims 1
- OJWJZWBDLPWDNW-UHFFFAOYSA-N Cl.Cl.Cl.Cl.NC1=NC=CC(=C1F)C1=NC(=C(C=C1)O)C1=NC(=NC(=C1)C1CN(CCC1)CCC)N Chemical compound Cl.Cl.Cl.Cl.NC1=NC=CC(=C1F)C1=NC(=C(C=C1)O)C1=NC(=NC(=C1)C1CN(CCC1)CCC)N OJWJZWBDLPWDNW-UHFFFAOYSA-N 0.000 claims 1
- HKAGZMWWSIJBLT-UHFFFAOYSA-N Cl.Cl.Cl.Cl.NC1=NC=CC(=C1F)C1=NC(=C(C=C1)O)C1=NC(=NC(=C1)N(C)C)N Chemical compound Cl.Cl.Cl.Cl.NC1=NC=CC(=C1F)C1=NC(=C(C=C1)O)C1=NC(=NC(=C1)N(C)C)N HKAGZMWWSIJBLT-UHFFFAOYSA-N 0.000 claims 1
- HMFQMRODGSRVHG-UHFFFAOYSA-N Cl.Cl.Cl.Cl.NC1=NC=CC(=C1F)C1=NC(=C(C=C1)O)C1=NC(=NC(=C1)N1CCOCC1)N Chemical compound Cl.Cl.Cl.Cl.NC1=NC=CC(=C1F)C1=NC(=C(C=C1)O)C1=NC(=NC(=C1)N1CCOCC1)N HMFQMRODGSRVHG-UHFFFAOYSA-N 0.000 claims 1
- LNGATKDKIKMRFU-UHFFFAOYSA-N Cl.Cl.Cl.Cl.NC1=NC=CC(=C1F)C1=NC(=C(C=C1)O)C1=NC(=NC(=C1CCC)C1CCN(CC1)C(C)C)N Chemical compound Cl.Cl.Cl.Cl.NC1=NC=CC(=C1F)C1=NC(=C(C=C1)O)C1=NC(=NC(=C1CCC)C1CCN(CC1)C(C)C)N LNGATKDKIKMRFU-UHFFFAOYSA-N 0.000 claims 1
- RREXIOBIIXDDAD-UHFFFAOYSA-N Cl.Cl.Cl.NC1=NC=CC(=C1F)C1=NC(=C(C=C1)O)C1(CN=C(N=C1)N)C(C)C Chemical compound Cl.Cl.Cl.NC1=NC=CC(=C1F)C1=NC(=C(C=C1)O)C1(CN=C(N=C1)N)C(C)C RREXIOBIIXDDAD-UHFFFAOYSA-N 0.000 claims 1
- ONBOKWWSQDCVEI-UHFFFAOYSA-N Cl.Cl.Cl.NC1=NC=CC(=C1F)C1=NC(=C(C=C1)O)C1=NC(=NC(=C1)C(C)C)N Chemical compound Cl.Cl.Cl.NC1=NC=CC(=C1F)C1=NC(=C(C=C1)O)C1=NC(=NC(=C1)C(C)C)N ONBOKWWSQDCVEI-UHFFFAOYSA-N 0.000 claims 1
- VRWBURQQJPINMR-UHFFFAOYSA-N Cl.Cl.Cl.NC1=NC=CC(=C1F)C1=NC(=C(C=C1)O)C1=NC(=NC(=C1)C)N Chemical compound Cl.Cl.Cl.NC1=NC=CC(=C1F)C1=NC(=C(C=C1)O)C1=NC(=NC(=C1)C)N VRWBURQQJPINMR-UHFFFAOYSA-N 0.000 claims 1
- UPSUYPOZKBCGJK-UHFFFAOYSA-N Cl.Cl.Cl.NC1=NC=CC(=C1F)C1=NC(=C(C=C1)O)C1=NC(=NC(=C1C)C)N Chemical compound Cl.Cl.Cl.NC1=NC=CC(=C1F)C1=NC(=C(C=C1)O)C1=NC(=NC(=C1C)C)N UPSUYPOZKBCGJK-UHFFFAOYSA-N 0.000 claims 1
- NJCDKCYDSFRTAW-UHFFFAOYSA-N Cl.Cl.Cl.NC1=NC=CC(=C1F)C1=NC(=C(C=C1)O)C1=NC(=NC=C1)N Chemical compound Cl.Cl.Cl.NC1=NC=CC(=C1F)C1=NC(=C(C=C1)O)C1=NC(=NC=C1)N NJCDKCYDSFRTAW-UHFFFAOYSA-N 0.000 claims 1
- REWOBGPMMIUEKR-UHFFFAOYSA-N Cl.Cl.Cl.NC1=NC=CC(=C1F)C1=NC(=C(C=C1)O)C1=NC(=NC=C1C)N Chemical compound Cl.Cl.Cl.NC1=NC=CC(=C1F)C1=NC(=C(C=C1)O)C1=NC(=NC=C1C)N REWOBGPMMIUEKR-UHFFFAOYSA-N 0.000 claims 1
- XJXXAGAPVLIOJN-UHFFFAOYSA-N Cl.Cl.Cl.NC1=NC=CC(=C1F)C1=NC(=C(C=C1)O)C1=NC(=NC=C1CC)N Chemical compound Cl.Cl.Cl.NC1=NC=CC(=C1F)C1=NC(=C(C=C1)O)C1=NC(=NC=C1CC)N XJXXAGAPVLIOJN-UHFFFAOYSA-N 0.000 claims 1
- YCBUYJCKKVCZTG-UHFFFAOYSA-N Cl.Cl.Cl.NC1=NC=CC(=C1F)C1=NC(=C(C=C1)O)C1=NC(=NC=C1CCC)N Chemical compound Cl.Cl.Cl.NC1=NC=CC(=C1F)C1=NC(=C(C=C1)O)C1=NC(=NC=C1CCC)N YCBUYJCKKVCZTG-UHFFFAOYSA-N 0.000 claims 1
- YUNYDIDVURXULR-UHFFFAOYSA-N Cl.Cl.Cl.Nc1nccc(n1)-c1ccc(O)c(n1)-c1ccnc(N)n1 Chemical compound Cl.Cl.Cl.Nc1nccc(n1)-c1ccc(O)c(n1)-c1ccnc(N)n1 YUNYDIDVURXULR-UHFFFAOYSA-N 0.000 claims 1
- BJIGHZRCSWAVDQ-UHFFFAOYSA-N Cl.Cl.NC1=NC=CC(=N1)C1=NC(=CC=C1O)C1=C(C=C(C=C1)O)F Chemical compound Cl.Cl.NC1=NC=CC(=N1)C1=NC(=CC=C1O)C1=C(C=C(C=C1)O)F BJIGHZRCSWAVDQ-UHFFFAOYSA-N 0.000 claims 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 1
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 claims 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 claims 1
- 108010069236 Goserelin Proteins 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- RRIUHYJWADWNIQ-UHFFFAOYSA-N NC1=NC=CC(=C1F)C1=NC(=C(C=C1)O)C1(CN=C(N=C1)N)C(C)C Chemical compound NC1=NC=CC(=C1F)C1=NC(=C(C=C1)O)C1(CN=C(N=C1)N)C(C)C RRIUHYJWADWNIQ-UHFFFAOYSA-N 0.000 claims 1
- DEMLSGPLUVQJBI-UHFFFAOYSA-N NC1=NC=CC(=C1F)C1=NC(=CC=C1)C1=NC(=NC(=C1CCC)C1CCN(CC1)C(C)C)N Chemical compound NC1=NC=CC(=C1F)C1=NC(=CC=C1)C1=NC(=NC(=C1CCC)C1CCN(CC1)C(C)C)N DEMLSGPLUVQJBI-UHFFFAOYSA-N 0.000 claims 1
- HTTWPPKPDRGXMH-UHFFFAOYSA-N NC1=NC=CC(C2=NC(C3=NC(N)=NC(C4CCOCC4)=C3)=CC=C2)=C1F Chemical compound NC1=NC=CC(C2=NC(C3=NC(N)=NC(C4CCOCC4)=C3)=CC=C2)=C1F HTTWPPKPDRGXMH-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- KONVZADYSPKKTC-UHFFFAOYSA-N OC(=O)C(O)=O.CN1CCC(CC1)c1cc(nc(N)n1)-c1nc(ccc1O)-c1ccnc(N)c1F Chemical compound OC(=O)C(O)=O.CN1CCC(CC1)c1cc(nc(N)n1)-c1nc(ccc1O)-c1ccnc(N)c1F KONVZADYSPKKTC-UHFFFAOYSA-N 0.000 claims 1
- LYBXDLUIXDJORF-UHFFFAOYSA-N OC(=O)C(O)=O.Nc1cc(ccn1)-c1cc(c(O)cn1)-c1ccnc(N)n1 Chemical compound OC(=O)C(O)=O.Nc1cc(ccn1)-c1cc(c(O)cn1)-c1ccnc(N)n1 LYBXDLUIXDJORF-UHFFFAOYSA-N 0.000 claims 1
- FBRYJBWOEXOWER-UHFFFAOYSA-N OC(=O)C(O)=O.Nc1nccc(n1)-c1ccc(O)c(n1)-c1ccnc(N)n1 Chemical compound OC(=O)C(O)=O.Nc1nccc(n1)-c1ccc(O)c(n1)-c1ccnc(N)n1 FBRYJBWOEXOWER-UHFFFAOYSA-N 0.000 claims 1
- UZODUUYKBVZPKA-UHFFFAOYSA-N OC(=O)C(O)=O.Nc1nccc(n1)-c1nc(ccc1O)-c1ccnc(N)c1F Chemical compound OC(=O)C(O)=O.Nc1nccc(n1)-c1nc(ccc1O)-c1ccnc(N)c1F UZODUUYKBVZPKA-UHFFFAOYSA-N 0.000 claims 1
- LHSFVGOQEOZTRD-UHFFFAOYSA-N OC(=O)CC(O)=O.Nc1nccc(n1)-c1ccc(O)c(n1)-c1ccnc(N)n1 Chemical compound OC(=O)CC(O)=O.Nc1nccc(n1)-c1ccc(O)c(n1)-c1ccnc(N)n1 LHSFVGOQEOZTRD-UHFFFAOYSA-N 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 claims 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- HWHLPVGTWGOCJO-UHFFFAOYSA-N Trihexyphenidyl Chemical group C1CCCCC1C(C=1C=CC=CC=1)(O)CCN1CCCCC1 HWHLPVGTWGOCJO-UHFFFAOYSA-N 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims 1
- UQOQEJLTTFBPRV-UHFFFAOYSA-N [2,6-bis(2-aminopyrimidin-4-yl)pyridin-3-yl] hydrogen sulfate Chemical compound S(=O)(=O)(O)OC=1C(=NC(=CC=1)C1=NC(=NC=C1)N)C1=NC(=NC=C1)N UQOQEJLTTFBPRV-UHFFFAOYSA-N 0.000 claims 1
- QMUKVCURZPNVBO-UHFFFAOYSA-N [6-(2-amino-3-fluoropyridin-4-yl)-2-(2-amino-6-morpholin-4-ylpyrimidin-4-yl)pyridin-3-yl] acetate Chemical compound C(C)(=O)OC=1C=CC(=NC=1C1=NC(=NC(=C1)N1CCOCC1)N)C1=C(C(=NC=C1)N)F QMUKVCURZPNVBO-UHFFFAOYSA-N 0.000 claims 1
- VXGITALTUQJXDC-UHFFFAOYSA-N [6-(2-amino-3-fluoropyridin-4-yl)-2-(2-amino-6-piperidin-4-ylpyrimidin-4-yl)pyridin-3-yl] acetate Chemical compound C(C)(=O)OC=1C=CC(=NC=1C1=NC(=NC(=C1)C1CCNCC1)N)C1=C(C(=NC=C1)N)F VXGITALTUQJXDC-UHFFFAOYSA-N 0.000 claims 1
- GEWSPJQJFOJPBX-UHFFFAOYSA-N [6-(2-amino-3-fluoropyridin-4-yl)-2-(2-aminopyrimidin-4-yl)pyridin-3-yl] acetate Chemical compound C(C)(=O)OC=1C=CC(=NC=1C1=NC(=NC=C1)N)C1=C(C(=NC=C1)N)F GEWSPJQJFOJPBX-UHFFFAOYSA-N 0.000 claims 1
- ISXLPRKKGRRLCL-UHFFFAOYSA-N [6-(2-amino-3-fluoropyridin-4-yl)-2-[2-amino-6-(4-methylpiperazin-1-yl)pyrimidin-4-yl]pyridin-3-yl] acetate Chemical compound C(C)(=O)OC=1C=CC(=NC=1C1=NC(=NC(=C1)N1CCN(CC1)C)N)C1=C(C(=NC=C1)N)F ISXLPRKKGRRLCL-UHFFFAOYSA-N 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 claims 1
- 229960003805 amantadine Drugs 0.000 claims 1
- 229960002932 anastrozole Drugs 0.000 claims 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 229940073770 avotaciclib Drugs 0.000 claims 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims 1
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 claims 1
- 229960002707 bendamustine Drugs 0.000 claims 1
- GIJXKZJWITVLHI-PMOLBWCYSA-N benzatropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(C=1C=CC=CC=1)C1=CC=CC=C1 GIJXKZJWITVLHI-PMOLBWCYSA-N 0.000 claims 1
- 229960001081 benzatropine Drugs 0.000 claims 1
- 229960000397 bevacizumab Drugs 0.000 claims 1
- 201000009036 biliary tract cancer Diseases 0.000 claims 1
- 208000020790 biliary tract neoplasm Diseases 0.000 claims 1
- 229960001561 bleomycin Drugs 0.000 claims 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims 1
- 229960002802 bromocriptine Drugs 0.000 claims 1
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229960004117 capecitabine Drugs 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 229960004562 carboplatin Drugs 0.000 claims 1
- 229960005243 carmustine Drugs 0.000 claims 1
- 229960005395 cetuximab Drugs 0.000 claims 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims 1
- 229960004630 chlorambucil Drugs 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- 210000003792 cranial nerve Anatomy 0.000 claims 1
- 229960004397 cyclophosphamide Drugs 0.000 claims 1
- 229960000684 cytarabine Drugs 0.000 claims 1
- 229960003668 docetaxel Drugs 0.000 claims 1
- 229960003530 donepezil Drugs 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- JRURYQJSLYLRLN-BJMVGYQFSA-N entacapone Chemical compound CCN(CC)C(=O)C(\C#N)=C\C1=CC(O)=C(O)C([N+]([O-])=O)=C1 JRURYQJSLYLRLN-BJMVGYQFSA-N 0.000 claims 1
- 229960003337 entacapone Drugs 0.000 claims 1
- 229960001904 epirubicin Drugs 0.000 claims 1
- 229960003649 eribulin Drugs 0.000 claims 1
- UFNVPOGXISZXJD-XJPMSQCNSA-N eribulin Chemical compound C([C@H]1CC[C@@H]2O[C@@H]3[C@H]4O[C@H]5C[C@](O[C@H]4[C@H]2O1)(O[C@@H]53)CC[C@@H]1O[C@H](C(C1)=C)CC1)C(=O)C[C@@H]2[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]2C[C@@H]2C(=C)[C@H](C)C[C@H]1O2 UFNVPOGXISZXJD-XJPMSQCNSA-N 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 229960005167 everolimus Drugs 0.000 claims 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 claims 1
- 229960002949 fluorouracil Drugs 0.000 claims 1
- 229960002258 fulvestrant Drugs 0.000 claims 1
- 229960003980 galantamine Drugs 0.000 claims 1
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 claims 1
- 201000010175 gallbladder cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 1
- 229960005277 gemcitabine Drugs 0.000 claims 1
- 229960002913 goserelin Drugs 0.000 claims 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
- 201000010759 hypertrophy of breast Diseases 0.000 claims 1
- 229960001101 ifosfamide Drugs 0.000 claims 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 229960003881 letrozole Drugs 0.000 claims 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 claims 1
- 229960004502 levodopa Drugs 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 229960002247 lomustine Drugs 0.000 claims 1
- 229960004961 mechlorethamine Drugs 0.000 claims 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 claims 1
- 229960001786 megestrol Drugs 0.000 claims 1
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 claims 1
- 229960004640 memantine Drugs 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims 1
- 229960001756 oxaliplatin Drugs 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 229960001972 panitumumab Drugs 0.000 claims 1
- 229960005079 pemetrexed Drugs 0.000 claims 1
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 claims 1
- 229960002087 pertuzumab Drugs 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 229960003089 pramipexole Drugs 0.000 claims 1
- FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 claims 1
- 229960005253 procyclidine Drugs 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Chemical group COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- LJXQPZWIHJMPQQ-UHFFFAOYSA-N pyrimidin-2-amine Chemical compound NC1=NC=CC=N1 LJXQPZWIHJMPQQ-UHFFFAOYSA-N 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 229960000245 rasagiline Drugs 0.000 claims 1
- RUOKEQAAGRXIBM-GFCCVEGCSA-N rasagiline Chemical compound C1=CC=C2[C@H](NCC#C)CCC2=C1 RUOKEQAAGRXIBM-GFCCVEGCSA-N 0.000 claims 1
- 229960004136 rivastigmine Drugs 0.000 claims 1
- 229960001879 ropinirole Drugs 0.000 claims 1
- UHSKFQJFRQCDBE-UHFFFAOYSA-N ropinirole Chemical compound CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 UHSKFQJFRQCDBE-UHFFFAOYSA-N 0.000 claims 1
- 229960003179 rotigotine Drugs 0.000 claims 1
- KFQYTPMOWPVWEJ-INIZCTEOSA-N rotigotine Chemical compound CCCN([C@@H]1CC2=CC=CC(O)=C2CC1)CCC1=CC=CS1 KFQYTPMOWPVWEJ-INIZCTEOSA-N 0.000 claims 1
- 229960003946 selegiline Drugs 0.000 claims 1
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 229960001603 tamoxifen Drugs 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- 229960000235 temsirolimus Drugs 0.000 claims 1
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 claims 1
- 229960005333 tetrabenazine Drugs 0.000 claims 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 229960001196 thiotepa Drugs 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 229960003087 tioguanine Drugs 0.000 claims 1
- MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 claims 1
- QQHMKNYGKVVGCZ-UHFFFAOYSA-N tipiracil Chemical compound N1C(=O)NC(=O)C(Cl)=C1CN1C(=N)CCC1 QQHMKNYGKVVGCZ-UHFFFAOYSA-N 0.000 claims 1
- 229960002952 tipiracil Drugs 0.000 claims 1
- 229960000303 topotecan Drugs 0.000 claims 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims 1
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 claims 1
- 229960005026 toremifene Drugs 0.000 claims 1
- 229960000575 trastuzumab Drugs 0.000 claims 1
- VSQQQLOSPVPRAZ-RRKCRQDMSA-N trifluridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C(F)(F)F)=C1 VSQQQLOSPVPRAZ-RRKCRQDMSA-N 0.000 claims 1
- 229960003962 trifluridine Drugs 0.000 claims 1
- 229960001032 trihexyphenidyl Drugs 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
- 229960003048 vinblastine Drugs 0.000 claims 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims 1
- 229960004528 vincristine Drugs 0.000 claims 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 claims 1
- 229960002066 vinorelbine Drugs 0.000 claims 1
- XFVSLZPVYJSNRM-UHFFFAOYSA-N CC(C)CN(C)COC Chemical compound CC(C)CN(C)COC XFVSLZPVYJSNRM-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2015-0017339 | 2015-02-04 | ||
| KR20150017339 | 2015-02-04 | ||
| PCT/KR2016/001133 WO2016126085A2 (ko) | 2015-02-04 | 2016-02-02 | 헤테로 고리 화합물 및 그를 포함하는 약제학적 조성물 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018504449A JP2018504449A (ja) | 2018-02-15 |
| JP2018504449A5 true JP2018504449A5 (enExample) | 2019-03-14 |
| JP6615899B2 JP6615899B2 (ja) | 2019-12-04 |
Family
ID=56564854
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017541860A Active JP6615899B2 (ja) | 2015-02-04 | 2016-02-02 | ヘテロ環化合物及びそれを含む薬剤学的組成物 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US10227328B2 (enExample) |
| EP (1) | EP3255042B1 (enExample) |
| JP (1) | JP6615899B2 (enExample) |
| KR (1) | KR101783642B1 (enExample) |
| CN (1) | CN107250130B (enExample) |
| AU (1) | AU2016216253B2 (enExample) |
| BR (1) | BR112017016465B1 (enExample) |
| CA (1) | CA2974788C (enExample) |
| DK (1) | DK3255042T3 (enExample) |
| ES (1) | ES2854707T3 (enExample) |
| IL (1) | IL253538B (enExample) |
| RU (1) | RU2710743C2 (enExample) |
| SG (1) | SG11201705952SA (enExample) |
| WO (1) | WO2016126085A2 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102444835B1 (ko) | 2016-05-26 | 2022-09-19 | 리커리엄 아이피 홀딩스, 엘엘씨 | Egfr 억제제 화합물 |
| EP3843741A4 (en) * | 2018-08-30 | 2022-11-30 | The Regents of the University of California | KINASE IRE1 INHIBITORS AND THEIR USES |
| CA3127958A1 (en) * | 2019-01-29 | 2020-08-06 | Beta Pharma, Inc. | 2h-indazole derivatives as therapeutic agents for brain cancers and brain metastases |
| WO2021045582A1 (ko) * | 2019-09-06 | 2021-03-11 | 비욘드바이오주식회사 | 2,6-비스-(2-아미노피리미딘-4-일)피리딘-3-올 2염산염 및 이를 포함하는 약제학적 조성물 |
| KR102443873B1 (ko) * | 2019-09-06 | 2022-09-19 | 비욘드바이오주식회사 | 피리미딘일 바이피리딘 화합물의 제조방법 및 그를 위한 중간체 |
| WO2021045586A1 (ko) * | 2019-09-06 | 2021-03-11 | 비욘드바이오주식회사 | 2'-아미노-6-(2-아미노-6-(1-이소프로필피페리딘-4-일)-5-메틸피리미딘-4-일)-3'-플루오로-[2,4'-바이피리딘]-5-올 3염산염 및 이를 포함하는 약제학적 조성물 |
| KR20210029694A (ko) | 2019-09-06 | 2021-03-16 | 비욘드바이오주식회사 | 2'-아미노-6-(2-아미노-6-메틸피리미딘-4-일)-3'-플루오로-[2,4'-바이피리딘]-5-올 2염산염 및 이를 포함하는 약제학적 조성물 |
| EP4062938A4 (en) * | 2019-11-18 | 2023-11-29 | Chugai Seiyaku Kabushiki Kaisha | COMBINATION MEDICINAL PRODUCTS |
| CN111558044B (zh) * | 2020-06-01 | 2022-02-11 | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | 一种包含舒尼替尼的药物组合物及其制剂和应用 |
| CN116082310B (zh) * | 2023-02-17 | 2024-08-20 | 厦门大学 | 联吡啶酰胺类衍生物及其制备和应用 |
| CN116751195B (zh) * | 2023-06-21 | 2025-03-07 | 杭州科兴生物化工有限公司 | 联吡啶类化合物、其可药用的盐以及制备方法和应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6440965B1 (en) * | 1997-10-15 | 2002-08-27 | Krenitsky Pharmaceuticals, Inc. | Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system |
| GB0013655D0 (en) * | 2000-06-05 | 2000-07-26 | Prolifix Ltd | Therapeutic compounds |
| NZ522773A (en) * | 2000-06-12 | 2005-06-24 | Eisai Co Ltd | 1,2-dihydropyridine compounds, manufacturing method thereof and use thereof |
| AU2002310187A1 (en) * | 2001-05-30 | 2002-12-09 | Lg Biomedical Institute | Inhibitors of protein kinase for the treatment of disease |
| GB0129260D0 (en) * | 2001-12-06 | 2002-01-23 | Eisai London Res Lab Ltd | Pharmaceutical compositions and their uses |
| KR20050042478A (ko) * | 2002-08-14 | 2005-05-09 | 버텍스 파마슈티칼스 인코포레이티드 | 프로테인 키나아제 억제제 및 이의 용도 |
| CN1742723A (zh) | 2004-09-02 | 2006-03-08 | 天津倍方科技发展有限公司 | 含有替莫唑胺－8－羧酸酯的药物组合物以及该类化合物用于制备抗肿瘤药物的用途 |
| WO2008106202A1 (en) * | 2007-02-27 | 2008-09-04 | Housey Gerard M | Theramutein modulators |
| WO2010018458A2 (en) * | 2008-08-12 | 2010-02-18 | Crystalgenomics, Inc. | Phenol derivatives and methods of use thereof |
-
2016
- 2016-02-02 US US15/546,714 patent/US10227328B2/en active Active
- 2016-02-02 WO PCT/KR2016/001133 patent/WO2016126085A2/ko not_active Ceased
- 2016-02-02 BR BR112017016465-5A patent/BR112017016465B1/pt active IP Right Grant
- 2016-02-02 EP EP16746826.3A patent/EP3255042B1/en active Active
- 2016-02-02 JP JP2017541860A patent/JP6615899B2/ja active Active
- 2016-02-02 SG SG11201705952SA patent/SG11201705952SA/en unknown
- 2016-02-02 AU AU2016216253A patent/AU2016216253B2/en active Active
- 2016-02-02 CN CN201680008749.8A patent/CN107250130B/zh active Active
- 2016-02-02 CA CA2974788A patent/CA2974788C/en active Active
- 2016-02-02 KR KR1020160013029A patent/KR101783642B1/ko active Active
- 2016-02-02 DK DK16746826.3T patent/DK3255042T3/da active
- 2016-02-02 ES ES16746826T patent/ES2854707T3/es active Active
- 2016-02-02 RU RU2017130825A patent/RU2710743C2/ru active
-
2017
- 2017-07-18 IL IL253538A patent/IL253538B/en active IP Right Grant
-
2019
- 2019-01-07 US US16/241,177 patent/US10611754B2/en active Active
-
2020
- 2020-02-21 US US16/798,134 patent/US20200190062A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018504449A5 (enExample) | ||
| RU2017130825A (ru) | Гетероциклическое соединение и содержащая его фармацевтическая композиция | |
| JP2012504628A5 (enExample) | ||
| ES2867048T3 (es) | Derivados deuterados de ruxolitinib | |
| SI3140303T1 (en) | Compounds of imidazo (4,5-c) quinolin-2-one and their use in the treatment of cancer | |
| JP2013544807A5 (enExample) | ||
| HRP20210548T1 (hr) | Spojevi amino-triazolopiridina i njihova uporaba u liječenju raka | |
| EP3280708A1 (en) | Substituted quinazoline compounds and methods of use thereof | |
| AU2016284816B2 (en) | Pharmaceutical co-crystal composition and use thereof | |
| JP2013541561A5 (enExample) | ||
| JP2013544846A5 (enExample) | ||
| JP2013529196A5 (enExample) | ||
| JP2012153722A5 (enExample) | ||
| RU2018120492A (ru) | ИМИДАЗО[4,5-c]ХИНОЛИН-2-ОНОВЫЕ СОЕДИНЕНИЯ И ИХ ПРИМЕНЕНИЕ В ЛЕЧЕНИИ РАКА | |
| JP2017506250A5 (enExample) | ||
| JP2014525464A5 (enExample) | ||
| JP2010522765A5 (enExample) | ||
| RU2015141772A (ru) | Новые соединения и композиции для ингибирования fasn | |
| RU2018122864A (ru) | Ингибиторы протеинкиназ, их способ получения и медицинское применение | |
| AU2020319058A1 (en) | Macrocyclic compounds as sting agonists and methods and uses thereof | |
| RU2011119525A (ru) | Производные морфолинопурина | |
| PH12015500883A1 (en) | Heteroaromatic compounds as dopamide d1 ligands | |
| AU2017205749B2 (en) | Use of quinoline derivatives for treating oesophageal cancer and treatment method, pharmaceutical composition and kit thereof | |
| JP2018534289A5 (enExample) | ||
| US20210401842A1 (en) | [6R]-MTHF - an efficient folate alternative in 5-fluorouracil based chemotherapy |